Zytiga (Abiraterone Acetate)
o Zytiga (abiraterone acetate) is an androgen biosynthesis inhibitor used in advanced prostate cancer to further suppress testosterone production beyond standard androgen deprivation therapy (ADT). It is typically used with prednisone to manage side effects.
o Blocks Androgen Production at Multiple Sources
1. Standard ADT (e.g., Lupron, Orgovyx) suppresses testicular testosterone production by inhibiting the hypothalamic-pituitary-gonadal (HPG) axis.
2. Zytiga goes further by blocking CYP17, an enzyme involved in androgen synthesis in the adrenal glands and prostate tumors.
3. This reduces residual androgens, which can still fuel prostate cancer even with ADT.
4. After discontinuing Zytiga it can take around a month for the enzymes to recover.
o Prevents the Synthesis of Key Androgens
1. CYP17 inhibition blocks the conversion of pregnenolone and progesterone into androgens like DHEA, androstenedione, and testosterone.
2. This starves prostate cancer cells of all possible androgen sources.
In 2019 I used tE2 for ADT and Zytiga to mop up any remaining biosynthesis. T held undetectable and so did PSA.
I'm thinking of adding it to pBAT. Thoughts?